NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

人類疫苗市場-全球產業分析,規模,佔有率,成長,趨勢,及預測(2016年∼2024年)

Human Vaccines Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

出版商 Transparency Market Research 商品編碼 974872
出版日期 內容資訊 英文 183 Pages
商品交期: 最快1-2個工作天內
價格
人類疫苗市場-全球產業分析,規模,佔有率,成長,趨勢,及預測(2016年∼2024年) Human Vaccines Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024
出版日期: 2020年10月30日內容資訊: 英文 183 Pages
簡介

本報告提供人類疫苗市場相關調查,市場概要,以及各疫苗,各產品,各流通管道,各年齡群,各地區的趨勢,及加入此市場的主要企業簡介等資訊。

目錄

第1章 序文

第2章 與假設調查手法

第3章 摘要整理:全球人類疫苗市場

第4章 市場概要

  • 簡介
  • 概要
  • 市場動態
    • 促進因素
    • 阻礙因素
    • 市場機會
  • 全球人類疫苗市場分析與預測,2018∼2030年

第5章 重要的洞察

  • 產品概要
  • 主要的產業的發展
  • 人類疫苗市場新的趨勢

第6章 全球人類疫苗市場分析與預測,各疫苗

  • 簡介和定義
  • 主要調查結果/開發
  • 各疫苗的市場價值預測,2018∼2030年
    • 結合疫苗
    • 重組疫苗
    • 不活化疫苗
    • 組合疫苗
    • 弱毒化疫苗
    • 其他
  • 各疫苗市場魅力

第7章 全球人類疫苗市場分析與預測,各產品

  • 簡介和定義
  • 主要調查結果/開發
  • 各產品的市場價值預測,2018∼2030年
    • 肺炎球菌
    • 流感
    • 肝炎
    • HPV
    • 腦膜炎
    • 輪狀病毒
    • 麻疹和德國麻疹
    • 傷寒症
    • 組合
    • 其他
  • 各產品的市場魅力

第8章 全球人類疫苗市場分析與預測,各流通管道

  • 簡介和定義
  • 主要調查結果/開發
  • 各流通管道的市場價值預測,2018∼2030年
    • 院內藥局
    • 藥妝店
    • 其他
  • 各流通管道的市場魅力

第9章 全球人類疫苗市場分析與預測,各年齡群

  • 簡介和定義
  • 主要調查結果/開發
  • 年齡群的市場價值預測,各2018∼ 2030年
    • 小兒科
    • 青年時期
    • 大人
    • 老年
  • 按年齡群的市場魅力

第10章 全球人類疫苗市場分析與預測,各地區

  • 主要調查結果
  • 各地區的市場價值預測
    • 北美
    • 歐洲
    • 亞太地區
    • 南美
    • 中東、非洲
  • 各地區的市場魅力

第11章 北美的人體疫苗市場分析與預測

  • 簡介
  • 市場價值預測,各疫苗,2018∼2030年
    • 結合疫苗
    • 重組疫苗
    • 不活化疫苗
    • 組合疫苗
    • 弱毒化疫苗
    • 其他
  • 市場價值預測,各產品,2018∼2030年
    • 肺炎球菌
    • 流感
    • 肝炎
    • HPV
    • 腦膜炎
    • 輪狀病毒
    • 麻疹和德國麻疹
    • 傷寒症
    • 組合
    • 其他
  • 市場價值預測,各流通管道,2018∼2030年
    • 院內藥局
    • 藥妝店
    • 其他
  • 市場價值預測,各年齡群,2018∼ 2030年
    • 小兒科
    • 青年時期
    • 大人
    • 老年醫學
  • 市場價值預測,各國,2018∼2030年
    • 美國
    • 加拿大
  • 市場魅力分析
    • 各疫苗
    • 各產品
    • 各流通管道
    • 各年齡群
    • 各國

第12章 歐洲的人類疫苗市場分析與預測

第13章 亞太地區的人體疫苗市場分析與預測

第14章 南美的人類疫苗市場分析與預測

第15章 中東及非洲的人類疫苗市場分析與預測

第16章 競爭情形

  • 各企業的市場佔有率分析(2019)
  • 企業簡介
    • AstraZeneca plc
    • Bavarian Nordic
    • Bharat Biotech
    • CSL Limited
    • Emergent BioSolutions, Inc.
    • GlaxoSmithKline plc.
    • Johnson & Johnson
    • Merck & Co, Inc.
    • Mymetics
    • Novartis AG
    • Pfizer, Inc.
    • Sanofi SA
    • 武田藥品工業株式會社
目錄
Product Code: TMRGL16127

Title:
Human Vaccines Market (Vaccine Type - Conjugate, Recombinant, Inactivated, Combination, and Attenuated; Product - Pneumococcal, Influenza, Hepatitis, HPV, Meningococcal, Rotavirus, Measles, Typhoid, and Combination; Age Group - Pediatrics, Adolescents, Adults, and Geriatrics; Distribution Channel - Hospital Pharmacies and Drugstores) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024.

Global Human Vaccine Market - Scope of Report

TMR's report on the global human vaccine market studies past as well as current growth trends and opportunities to gain valuable insights of these indicators of the market during the forecast period from 2019 to 2027. The report provides revenue of the global human vaccine market for the period 2017-2027, considering 2018 as the base year and 2027 as the forecast year. The report also provides the compound annual growth rate (CAGR) for the global human vaccine market during the forecast period.

The report has been prepared after an extensive primary and secondary research. Primary research involved bulk of research efforts, wherein analysts carried out interviews with industry leaders and opinion makers. Extensive secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the global human vaccine market.

Secondary research also included Internet sources, statistical data from government agencies, websites, company presentations, sales data, and trade associations. Analysts have employed a combination of top-down and bottom-up approaches to study various phenomenon in the global human vaccine market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Furthermore, the report sheds light on the changing competitive dynamics in the global human vaccine market. These indices serve as valuable tools for existing market players as well as for entities interested in entering the global human vaccine market.

The report delves into the competitive landscape of the global human vaccine market. Key players operating in the global human vaccine market have been identified, and each one of these has been profiled for distinguishing business attributes. Company overview, financial standings, recent developments, and SWOT are some of the attributes of players in the global human vaccine market that have been profiled in this report.

Key Questions Answered in Global Human vaccine Market Report

What is the scope of growth of product companies in the global human vaccine market?

What will be the Y-o-Y growth of the global human vaccine market between 2019 and 2027?

What is the influence of changing trends in technologies on the global human vaccine market?

Will North America continue to be the most profitable market for human vaccine providers?

Which factors are anticipated to hamper the growth of the global human vaccine market during the forecast period?

Which are the leading companies in the global human vaccine market?

Research Methodology

A unique research methodology has been utilized by TMR to conduct comprehensive research on the growth of the global human vaccine market and arrive at conclusions on its growth prospects. This research methodology is a combination of primary and secondary research, which helps analysts warrant the accuracy and reliability of the drawn conclusions.

Secondary methods referred to by analysts during the production of the global human vaccine market report include statistics from company annual reports, SEC filings, company websites, investor presentations, regulatory databases, government publications, and industry white papers. Analysts have also interviewed senior managers, product portfolio managers, CEOs, VPs, and market intelligence managers, who contributed to the production of TMR's study on the human vaccine market as primary methods.

These primary and secondary methods have provided exclusive information during interviews, which serves as a validation from the human vaccine market leaders. Access to an extensive internal repository and external proprietary databases enabled this report to address specific details and questions about the global human vaccine market with accuracy. The study also uses the top-down approach to assess the revenues for each segment and the bottom-up approach to counter-validate them. This has helped in reaching TMR's estimates on future prospects of the global human vaccine market more reliably and accurately.

Regional Segmentation of Human vaccine Market

North America

U.S.

Canada

Europe

Germany

U.K.

France

Italy

Spain

Rest of Europe

Asia Pacific

China

Japan

India

Australia & New Zealand

Rest of Asia Pacific

Latin America

Brazil

Mexico

Rest of Latin America

Middle East & Africa

GCC Countries

South Africa

Rest of Middle East & Africa

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Human Vaccine Market

4. Market Overview

  • 4.1. Introduction
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Human Vaccine Market Analysis and Forecasts, 2018-2030

5. Key Insights

  • 5.1. Product Overview
  • 5.2. Key Industry Developments
  • 5.3. Emerging Trends in Human Vaccines Market

6. Global Human Vaccine Market Analysis and Forecasts, By Vaccine

  • 6.1. Introduction & Definition
  • 6.2. Key Findings / Developments
  • 6.3. Market Value Forecast By Vaccine, 2018-2030
    • 6.3.1. Conjugate
    • 6.3.2. Recombinant
    • 6.3.3. Inactivated
    • 6.3.4. Combination
    • 6.3.5. Attenuated
    • 6.3.6. Others
  • 6.4. Market Attractiveness By Vaccine

7. Global Human Vaccine Market Analysis and Forecasts, By Product

  • 7.1. Introduction & Definition
  • 7.2. Key Findings / Developments
  • 7.3. Market Value Forecast By Product, 2018-2030
    • 7.3.1. Pneumococcal
    • 7.3.2. Influenza
    • 7.3.3. Hepatitis
    • 7.3.4. HPV
    • 7.3.5. Meningococcal
    • 7.3.6. Rotavirus
    • 7.3.7. Measles and Rubella
    • 7.3.8. Typhoid
    • 7.3.9. Combination
    • 7.3.10. Others
  • 7.4. Market Attractiveness By Product

8. Global Human Vaccine Market Analysis and Forecasts, By Distribution Channel

  • 8.1. Introduction & Definition
  • 8.2. Key Findings / Developments
  • 8.3. Market Value Forecast By Distribution Channel, 2018-2030
    • 8.3.1. Hospital Pharmacies
    • 8.3.2. Drugstores
    • 8.3.3. Others
  • 8.4. Market Attractiveness By Distribution Channel

9. Global Human Vaccine Market Analysis and Forecasts, By Age Group

  • 9.1. Introduction & Definition
  • 9.2. Key Findings / Developments
  • 9.3. Market Value Forecast By Age Group, 2018-2030
    • 9.3.1. Pediatrics
    • 9.3.2. Adolescents
    • 9.3.3. Adults
    • 9.3.4. Geriatrics
  • 9.4. Market Attractiveness By Age Group

10. Global Human Vaccine Market Analysis and Forecasts, By Region

  • 10.1. Key Findings
  • 10.2. Market Value Forecast By Region
    • 10.2.1. North America
    • 10.2.2. Europe
    • 10.2.3. Asia Pacific
    • 10.2.4. Latin America
    • 10.2.5. Middle East & Africa
  • 10.3. Market Attractiveness By Region

11. North America Human Vaccine Market Analysis and Forecast

  • 11.1. Introduction
  • 11.2. Market Value Forecast By Vaccine, 2018-2030
    • 11.2.1. Conjugate
    • 11.2.2. Recombinant
    • 11.2.3. Inactivated
    • 11.2.4. Combination
    • 11.2.5. Attenuated
    • 11.2.6. Others
  • 11.3. Market Value Forecast By Product, 2018-2030
    • 11.3.1. Pneumococcal
    • 11.3.2. Influenza
    • 11.3.3. Hepatitis
    • 11.3.4. HPV
    • 11.3.5. Meningococcal
    • 11.3.6. Rotavirus
    • 11.3.7. Measles and Rubella
    • 11.3.8. Typhoid
    • 11.3.9. Combination
    • 11.3.10. Others
  • 11.4. Market Value Forecast By Distribution Channel, 2018-2030
    • 11.4.1. Hospital Pharmacies
    • 11.4.2. Drugstores
    • 11.4.3. Others
  • 11.5. Market Value Forecast By Age Group, 2018-2030
    • 11.5.1. Pediatrics
    • 11.5.2. Adolescents
    • 11.5.3. Adults
    • 11.5.4. Geriatrics
  • 11.6. Market Value Forecast By Country, 2018-2030
    • 11.6.1. U.S.
    • 11.6.2. Canada
  • 11.7. Market Attractiveness Analysis
    • 11.7.1. By Vaccine
    • 11.7.2. By Product
    • 11.7.3. By Distribution Channel
    • 11.7.4. By Age Group
    • 11.7.5. By Country

12. Europe Human Vaccine Market Analysis and Forecast

  • 12.1. Introduction
  • 12.2. Market Value Forecast By Vaccine, 2018-2030
    • 12.2.1. Conjugate
    • 12.2.2. Recombinant
    • 12.2.3. Inactivated
    • 12.2.4. Combination
    • 12.2.5. Attenuated
    • 12.2.6. Others
  • 12.3. Market Value Forecast By Product, 2018-2030
    • 12.3.1. Pneumococcal
    • 12.3.2. Influenza
    • 12.3.3. Hepatitis
    • 12.3.4. HPV
    • 12.3.5. Meningococcal
    • 12.3.6. Rotavirus
    • 12.3.7. Measles and Rubella
    • 12.3.8. Typhoid
    • 12.3.9. Combination
    • 12.3.10. Others
  • 12.4. Market Value Forecast By Distribution Channel, 2018-2030
    • 12.4.1. Hospital Pharmacies
    • 12.4.2. Drugstores
    • 12.4.3. Others
  • 12.5. Market Value Forecast By Age Group, 2018-2030
    • 12.5.1. Pediatrics
    • 12.5.2. Adolescents
    • 12.5.3. Adults
    • 12.5.4. Geriatrics
  • 12.6. Market Value Forecast By Country, 2018-2030
    • 12.6.1. Germany
    • 12.6.2. U.K.
    • 12.6.3. France
    • 12.6.4. Spain
    • 12.6.5. Italy
    • 12.6.6. Rest of Europe
  • 12.7. Market Attractiveness Analysis
    • 12.7.1. By Vaccine
    • 12.7.2. By Product
    • 12.7.3. By Distribution Channel
    • 12.7.4. By Age Group
    • 12.7.5. By Country

13. Asia Pacific Human Vaccine Market Analysis and Forecast

  • 13.1. Introduction
  • 13.2. Market Value Forecast By Vaccine, 2018-2030
    • 13.2.1. Conjugate
    • 13.2.2. Recombinant
    • 13.2.3. Inactivated
    • 13.2.4. Combination
    • 13.2.5. Attenuated
    • 13.2.6. Others
  • 13.3. Market Value Forecast By Product, 2018-2030
    • 13.3.1. Pneumococcal
    • 13.3.2. Influenza
    • 13.3.3. Hepatitis
    • 13.3.4. HPV
    • 13.3.5. Meningococcal
    • 13.3.6. Rotavirus
    • 13.3.7. Measles and Rubella
    • 13.3.8. Typhoid
    • 13.3.9. Combination
    • 13.3.10. Others
  • 13.4. Market Value Forecast By Distribution Channel, 2018-2030
    • 13.4.1. Hospital Pharmacies
    • 13.4.2. Drugstores
    • 13.4.3. Others
  • 13.5. Market Value Forecast By Age Group, 2018-2030
    • 13.5.1. Pediatrics
    • 13.5.2. Adolescents
    • 13.5.3. Adults
    • 13.5.4. Geriatrics
  • 13.6. Market Value Forecast By Country, 2018-2030
    • 13.6.1. China
    • 13.6.2. Japan
    • 13.6.3. India
    • 13.6.4. Australia & New Zealand
    • 13.6.5. Rest of Asia Pacific
  • 13.7. Market Attractiveness Analysis
    • 13.7.1. By Vaccine
    • 13.7.2. By Product
    • 13.7.3. By Distribution Channel
    • 13.7.4. By Age Group
    • 13.7.5. By Country

14. Latin America Human Vaccine Market Analysis and Forecast

  • 14.1. Introduction
  • 14.2. Market Value Forecast By Vaccine, 2018-2030
    • 14.2.1. Conjugate
    • 14.2.2. Recombinant
    • 14.2.3. Inactivated
    • 14.2.4. Combination
    • 14.2.5. Attenuated
    • 14.2.6. Others
  • 14.3. Market Value Forecast By Product, 2018-2030
    • 14.3.1. Pneumococcal
    • 14.3.2. Influenza
    • 14.3.3. Hepatitis
    • 14.3.4. HPV
    • 14.3.5. Meningococcal
    • 14.3.6. Rotavirus
    • 14.3.7. Measles and Rubella
    • 14.3.8. Typhoid
    • 14.3.9. Combination
    • 14.3.10. Others
  • 14.4. Market Value Forecast By Distribution Channel, 2018-2030
    • 14.4.1. Hospital Pharmacies
    • 14.4.2. Drugstores
    • 14.4.3. Others
  • 14.5. Market Value Forecast By Age Group, 2018-2030
    • 14.5.1. Pediatrics
    • 14.5.2. Adolescents
    • 14.5.3. Adults
    • 14.5.4. Geriatrics
  • 14.6. Market Value Forecast By Country, 2018-2030
    • 14.6.1. Brazil
    • 14.6.2. Mexico
    • 14.6.3. Rest of Latin America
  • 14.7. Market Attractiveness Analysis
    • 14.7.1. By Vaccine
    • 14.7.2. By Product
    • 14.7.3. By Distribution Channel
    • 14.7.4. By Age Group
    • 14.7.5. By Country

15. Middle East & Africa Human Vaccine Market Analysis and Forecast

  • 15.1. Introduction
  • 15.2. Market Value Forecast By Vaccine, 2018-2030
    • 15.2.1. Conjugate
    • 15.2.2. Recombinant
    • 15.2.3. Inactivated
    • 15.2.4. Combination
    • 15.2.5. Attenuated
    • 15.2.6. Others
  • 15.3. Market Value Forecast By Product, 2018-2030
    • 15.3.1. Pneumococcal
    • 15.3.2. Influenza
    • 15.3.3. Hepatitis
    • 15.3.4. HPV
    • 15.3.5. Meningococcal
    • 15.3.6. Rotavirus
    • 15.3.7. Measles and Rubella
    • 15.3.8. Typhoid
    • 15.3.9. Combination
    • 15.3.10. Others
  • 15.4. Market Value Forecast By Distribution Channel, 2018-2030
    • 15.4.1. Hospital Pharmacies
    • 15.4.2. Drugstores
    • 15.4.3. Others
  • 15.5. Market Value Forecast By Age Group, 2018-2030
    • 15.5.1. Pediatrics
    • 15.5.2. Adolescents
    • 15.5.3. Adults
    • 15.5.4. Geriatrics
  • 15.6. Market Value Forecast By Country, 2018-2030
    • 15.6.1. GCC Countries
    • 15.6.2. South Africa
    • 15.6.3. Rest of Middle East & Africa
  • 15.7. Market Attractiveness Analysis
    • 15.7.1. By Vaccine
    • 15.7.2. By Product
    • 15.7.3. By Distribution Channel
    • 15.7.4. By Age Group
    • 15.7.5. By Country

16. Competition Landscape

  • 16.1. Market Share Analysis By Company (2019)
  • 16.2. Company Profiles
    • 16.2.1. AstraZeneca plc
      • 16.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.2.1.2. Growth Strategies
      • 16.2.1.3. SWOT Analysis
    • 16.2.2. Bavarian Nordic
      • 16.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.2.2.2. Growth Strategies
      • 16.2.2.3. SWOT Analysis
    • 16.2.3. Bharat Biotech
      • 16.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.2.3.2. Growth Strategies
      • 16.2.3.3. SWOT Analysis
    • 16.2.4. CSL Limited
      • 16.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.2.4.2. Growth Strategies
      • 16.2.4.3. SWOT Analysis
    • 16.2.5. Emergent BioSolutions, Inc.
      • 16.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.2.5.2. Growth Strategies
      • 16.2.5.3. SWOT Analysis
    • 16.2.6. GlaxoSmithKline plc.
      • 16.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.2.6.2. Growth Strategies
      • 16.2.6.3. SWOT Analysis
    • 16.2.7. Johnson & Johnson
      • 16.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.2.7.2. Growth Strategies
      • 16.2.7.3. SWOT Analysis
    • 16.2.8. Merck & Co, Inc.
      • 16.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.2.8.2. Growth Strategies
      • 16.2.8.3. SWOT Analysis
    • 16.2.9. Mymetics
      • 16.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.2.9.2. Growth Strategies
      • 16.2.9.3. SWOT Analysis
    • 16.2.10. Novartis AG
      • 16.2.10.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.2.10.2. Growth Strategies
      • 16.2.10.3. SWOT Analysis
    • 16.2.11. Pfizer, Inc.
      • 16.2.11.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.2.11.2. Growth Strategies
      • 16.2.11.3. SWOT Analysis
    • 16.2.12. Sanofi S.A.
      • 16.2.12.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.2.12.2. Growth Strategies
      • 16.2.12.3. SWOT Analysis
    • 16.2.13. Shenzhen Kangtai Biological Products Co., Ltd.
      • 16.2.13.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.2.13.2. Growth Strategies
      • 16.2.13.3. SWOT Analysis
    • 16.2.14. Takeda Pharmaceutical Company Limited
      • 16.2.14.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.2.14.2. Growth Strategies
      • 16.2.14.3. SWOT Analysis

List of Tables

Table 01 Global Human Vaccines Market Size (US$ Mn) Forecast, by Vaccine Type, 2019-2027

Table 02 Global Human Vaccines Market Size (US$ Mn) Forecast, by Product, 2019-2027

Table 03 Global Human Vaccines Market Size (US$ Mn) Forecast, by Distribution Channel, 2019-2027

Table 04 Global Human Vaccines Market Size (US$ Mn) Forecast, by Age Group, 2019-2027

Table 05 Global Human Vaccines Market Size (US$ Mn) Forecast, by Region, 2019-2027

Table 06 Asia Pacific Human Vaccines Market Size (US$ Mn) Forecast, by Country, 2019-2027

Table 07 Asia Pacific Human Vaccines Market Size (US$ Mn) Forecast, by Product, 2019-2027

Table 08 Asia Pacific Human Vaccines Market Size (US$ Mn) Forecast, by Vaccine Type, 2019-2027

Table 09 Asia Pacific Human Vaccines Market Size (US$ Mn) Forecast, by Age Group, 2019-2027

Table 10 Asia Pacific Human Vaccines Market Size (US$ Mn) Forecast, by Distribution Channel, 2019-2027

Table 11 North America Human Vaccines Market Size (US$ Mn) Forecast, by Country, 2019-2027

Table 12 North America Human Vaccines Market Size (US$ Mn) Forecast, by Product, 2019-2027

Table 13 North America Human Vaccines Market Size (US$) Forecast, by Vaccine Type, 2019-2027

Table 14 North America Human Vaccines Market Size (US$ Mn) Forecast, by Age Group, 2019-2027

Table 15 North America Human Vaccines Market Size (US$ Mn) Forecast, by Distribution Channel, 2019-2027

Table 16 Europe Human Vaccines Market Size (US$ Mn) Forecast, by Country, 2019-2027

Table 17 Europe Human Vaccines Market Size (US$ Mn) Forecast, by Product, 2019-2027

Table 18 Europe Human Vaccines Market Size (US$ Mn) Forecast, by Vaccine Type, 2019-2027

Table 19 Europe Human Vaccines Market Size (US$ Mn) Forecast, by Age Group, 2019-2027

Table 20 Europe Human Vaccines Market Size (US$ Mn) Forecast, by Distribution Channel, 2019-2027

Table 21 Latin America Human Vaccines Market Size (US$ Mn) Forecast, by Country, 2019-2027

Table 22 Latin America Human Vaccines Market Size (US$ Mn) Forecast, by Product, 2019-2027

Table 23 Latin America Human Vaccines Market Size (US$ Mn) Forecast, by Vaccine Type, 2019-2027

Table 24 Latin America Human Vaccines Market Size (US$ Mn) Forecast, by Age Group, 2019-2027

Table 25 Latin America Human Vaccines Market Size (US$ Mn) Forecast, by Distribution Channel, 2019-2027

Table 26 MEA Human Vaccines Market Size (US$ Mn) Forecast, by Country, 2019-2027

Table 27 MEA Human Vaccines Market Size (US$ Mn) Forecast, by Product, 2019-2027

Table 28 MEA Human Vaccines Market Size (US$ Mn) Forecast, by Vaccine Type, 2019-2027

Table 29 MEA Human Vaccines Market Size (US$ Mn) Forecast, by Age Group, 2019-2027

Table 30 MEA Human Vaccines Market Size (US$ Mn) Forecast, by Distribution Channel, 2019-2027

List of Tables

Table 01 Global Human Vaccines Market Size (US$ Mn) Forecast, by Vaccine Type, 2019-2027

Table 02 Global Human Vaccines Market Size (US$ Mn) Forecast, by Product, 2019-2027

Table 03 Global Human Vaccines Market Size (US$ Mn) Forecast, by Distribution Channel, 2019-2027

Table 04 Global Human Vaccines Market Size (US$ Mn) Forecast, by Age Group, 2019-2027

Table 05 Global Human Vaccines Market Size (US$ Mn) Forecast, by Region, 2019-2027

Table 06 Asia Pacific Human Vaccines Market Size (US$ Mn) Forecast, by Country, 2019-2027

Table 07 Asia Pacific Human Vaccines Market Size (US$ Mn) Forecast, by Product, 2019-2027

Table 08 Asia Pacific Human Vaccines Market Size (US$ Mn) Forecast, by Vaccine Type, 2019-2027

Table 09 Asia Pacific Human Vaccines Market Size (US$ Mn) Forecast, by Age Group, 2019-2027

Table 10 Asia Pacific Human Vaccines Market Size (US$ Mn) Forecast, by Distribution Channel, 2019-2027

Table 11 North America Human Vaccines Market Size (US$ Mn) Forecast, by Country, 2019-2027

Table 12 North America Human Vaccines Market Size (US$ Mn) Forecast, by Product, 2019-2027

Table 13 North America Human Vaccines Market Size (US$) Forecast, by Vaccine Type, 2019-2027

Table 14 North America Human Vaccines Market Size (US$ Mn) Forecast, by Age Group, 2019-2027

Table 15 North America Human Vaccines Market Size (US$ Mn) Forecast, by Distribution Channel, 2019-2027

Table 16 Europe Human Vaccines Market Size (US$ Mn) Forecast, by Country, 2019-2027

Table 17 Europe Human Vaccines Market Size (US$ Mn) Forecast, by Product, 2019-2027

Table 18 Europe Human Vaccines Market Size (US$ Mn) Forecast, by Vaccine Type, 2019-2027

Table 19 Europe Human Vaccines Market Size (US$ Mn) Forecast, by Age Group, 2019-2027

Table 20 Europe Human Vaccines Market Size (US$ Mn) Forecast, by Distribution Channel, 2019-2027

Table 21 Latin America Human Vaccines Market Size (US$ Mn) Forecast, by Country, 2019-2027

Table 22 Latin America Human Vaccines Market Size (US$ Mn) Forecast, by Product, 2019-2027

Table 23 Latin America Human Vaccines Market Size (US$ Mn) Forecast, by Vaccine Type, 2019-2027

Table 24 Latin America Human Vaccines Market Size (US$ Mn) Forecast, by Age Group, 2019-2027

Table 25 Latin America Human Vaccines Market Size (US$ Mn) Forecast, by Distribution Channel, 2019-2027

Table 26 MEA Human Vaccines Market Size (US$ Mn) Forecast, by Country, 2019-2027

Table 27 MEA Human Vaccines Market Size (US$ Mn) Forecast, by Product, 2019-2027

Table 28 MEA Human Vaccines Market Size (US$ Mn) Forecast, by Vaccine Type, 2019-2027

Table 29 MEA Human Vaccines Market Size (US$ Mn) Forecast, by Age Group, 2019-2027

Table 30 MEA Human Vaccines Market Size (US$ Mn) Forecast, by Distribution Channel, 2019-2027